Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

ESC Updates Guidance on Management of Acute Pulmonary Embolism

News Conference News ESC 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

September 06, 2019

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

News Conference News ESC 2016

Simplified VTE Protocol Rules Out Pulmonary Embolism, Reduces Use of CT Imaging: YEARS Study

Michael O'Riordan

September 02, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.